Whole-body magnetic resonance imaging for diagnosis and treatment monitoring in multiple myeloma
https://doi.org/10.35754/0234-5730-2020-65-4-431-443
Abstract
Introduction. Whole-body diffusion-weighted magnetic resonance imaging (MRI) is an informative method for bone marrow infiltration diagnosis in patients with multiple myeloma (MM) and post-monitoring in autologous haematopoietic stem cell transplantation (auto-HSCT).
Aim: to study bone marrow lesions in MM patients using whole-body MRI prior to and after chemotherapy with subsequent auto-HSCT.
Materials and methods. Forty patients with MM were included in a prospective study of whole-body MRI before and after high-dose chemotherapy with auto-HSCT. All patients had whole-body MRI prior to and at +100 day of auto-HSCT. Antitumour response was assessed after induction and at +100 day. The number and volume of bone marrow lesions prior to and at +100 day of auto-HSCT were determined, along with apparent diffusion coefficient (ADC) in the lesions.
Results. We observed a significant reduction of 29 % in the number of lesions, 40 % — in their volume and 33 % — in ADC. A significant correlation was revealed between relative reduction in the number and volume of foci (r = 0.52, p = 0.0017). A correlation was found between relative reduction in the foci number and ADC (r = 0.47, p = 0.016). Patients with lesions > 7 cm3 in MRI data exhibited a lesser reduction in the foci number and volume and ADC values after auto-HSCT compared to patients with lesions < 7 cm3.
Conclusion. Whole-body MRI with diffusion-weighted imaging and subsequent estimation of the number and volume of lesions and their ADC values prior to and after auto-HSCT add power to assessing antitumour response in MM patients with auto-HSCT.
About the Authors
N. S. Lutsik
National Research Center for Hematology
Russian Federation
Russian Federation
Natalia S. Lutsik, Radiologist, Department of Magnetic Resonance Imaging and Ultrasound
125167, Moscow
L. P. Mendeleeva
National Research Center for Hematology
Russian Federation
Russian Federation
Larisa P. Mendeleeva, Dr. Sci. (Med.), Professor, Deputy Director for Research and Innovation
125167, Moscow
M. V. Solovev
National Research Center for Hematology
Russian Federation
Russian Federation
Maxim V. Solovev, Cand. Sci. (Med.), Head of the Department of Intensive High-Dose Chemotherapy for Paraproteinemic Hemoblastoses
125167, Moscow
S. M. Kulikov
National Research Center for Hematology
Russian Federation
Russian Federation
Sergey M. Kulikov, Cand. Sci. (Tech.), Head of the Information and Analysis Department
125167, Moscow
Yu. A. Chabaeva
National Research Center for Hematology
Russian Federation
Russian Federation
Yulia A. Chabaeva, Cand. Sci. (Tech.), Senior Researcher, Information and Analysis Department
125167, Moscow
G. A. Yatsyk
National Research Center for Hematology
Russian Federation
Russian Federation
Galina A. Yatsyk, Cand. Sci. (Med.), Radiologist, Head of the Department of Magnetic Resonance Imaging and Ultrasound
125167, Moscow
References
1. Mendeleeva L.P., Votyakova O.M., Pokrovskaya O.S. et al. National clinical guidelines on diagnosis and treatment of multiple myeloma. Gematologiya i transfuziologiya. 2016; 61(1): (Suppl 2): 24. DOI: 10.18821/0234-5730-2016-61-1. (In Russian).
2. Rajkumar S.V., Dimopoulos M.A., Palumbo A. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12): e538–48. DOI: 10.1016/S1470-2045(14)70442-5.
3. Terpos E., Dimopoulos M.A., Moulopoulos L.A. The role of imaging in the treatment of patients with multiple myeloma in 2016. Am Soc Clin Oncol Educ Book. 2016; 35: e407–17. DOI: 10.14694/EDBK_159074.
4. Mahnken A.H., Wildberger J.E., Gehbauer G. et al. Multidetector CT of the spine in multiple myeloma: Comparison with MR imaging and radiography. Am J Roentgenol. 2002; 178(6): 1429–36. DOI: 10.2214/ajr.178.6.1781429.
5. Healy C.F., Murray J.G., Eustace S.J. et al. Multiple myeloma: A review of imaging features and radiological techniques. Bone Marrow Res. 2011; 2011: 1–9. DOI: 10.1155/2011/583439.
6. Dimopoulos M.A., Hillengass J., Usmani S. et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: A consensus statement. J Clin Oncol. 2015; 33(6): 657–64. DOI: 10.1200/JCO.2014.57.9961.
7. Moulopoulos L.A., Gika D., Anagnostopoulos A. et al. Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. Ann Oncol. 2005; 16(11): 1824–8. DOI: 10.1093/annonc/mdi362.
8. Walker R., Barlogie B., Haessler J. et al. Magnetic resonance imaging in multiple myeloma: Diagnostic and clinical implications. J Clin Oncol. 2007; 25(9): 1121–8. DOI: 10.1200/JCO.2006.08.5803.
9. Dutoit J.C., Verstraete K.L. MRI in multiple myeloma: a pictorial review of diagnostic and post-treatment findings. Insights Imaging. 2016; 7(4): 553–69. DOI: 10.1007/s13244-016-0492-7.
10. Ferrari C., Minoia C., Asabella A.N. et al. Whole body magnetic resonance with diffusion weighted sequence with body signal suppression compared to (18) F-FDG PET/CT in newly diagnosed lymphoma. Hell J Nucl Med. 2014; 17(Suppl 1): 40–9.
11. Horger M., Weisel K., Horger W. et al. Whole-body diffusion-weighted MRI with apparent diffusion coefficient mapping for early response monitoring in multiple myeloma: Preliminary results. Am J Roentgenol. 2011; 196(6): W790–5. DOI: 10.2214/AJR.10.5979.
12. Lin C., Luciani A., Itti E. et al. Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma. Eur Radiol. 2010; 20(8): 2027–38. DOI: 10.1007/s00330-010-1758-y.
13. Sachpekidis C., Hillengass J., Goldschmidt H. et al. Comparison of (18)F-FDG PET/CT and PET/MRI in patients with multiple myeloma. Am J Nucl Med Mol Imaging. 2015; 5(5): 469–78.
14. Solovev M.V., Mendeleeva L.P., Yatsyk G.A. et al. Monitoring bone marrow lesions by magnetic resonance imaging in patients with multiple myeloma after autologous stem cell transplantation. Gematologiya i transfuziologiya. 2018; 63(2): 103–12. DOI: 10.25837/HAT.2018.67..2..001. (In Russian).
15. Hillengass J., Ayyaz S., Kilk K. et al. Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma. Haematologica. 2012; 97(11): 1757–60. DOI: 10.3324/haematol.2012.065359.
16. Stecco A., Buemi F., Iannessi A. et al. Current concepts in tumor imaging with whole-body MRI with diffusion imaging (WB-MRI-DWI) in multiple myeloma and lymphoma. Leuk Lymphoma. 2018; 59(11): 2546–56. DOI: 10.1080/10428194.2018.1434881.
17. Padhani A.R., Liu G., Mu-Koh D. et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: Consensus and recommendations. Neoplasia. 2009; 11(2): 102–25. DOI: 10.1593/neo.81328.
Review
For citations:
Lutsik N.S., Mendeleeva L.P., Solovev M.V., Kulikov S.M., Chabaeva Yu.A., Yatsyk G.A. Whole-body magnetic resonance imaging for diagnosis and treatment monitoring in multiple myeloma. Russian journal of hematology and transfusiology. 2020;65(4):431-443. (In Russ.) https://doi.org/10.35754/0234-5730-2020-65-4-431-443
Views:
4524
Email this article 
